title: Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
authors.forename: Gareth J
authors.initials: GJ
authors.lastname: Morgan
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Schey
authors.forename: Ping
authors.initials: P
authors.lastname: Wu
authors.forename: Muralikrishan
authors.initials: M
authors.lastname: Srikanth
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Phekoo
authors.forename: Matthew
authors.initials: M
authors.lastname: Jenner
authors.forename: Faith E
authors.initials: FE
authors.lastname: Davies
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012189:Retrospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D003907:Dexamethasone; D003520:Cyclophosphamide; D000077269:Lenalidomide